Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-08-06
2003-01-28
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S183000, C514S217080, C514S291000, C514S330000, C514S331000, C514S874000, C514S922000
Reexamination Certificate
active
06511986
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates the use of a combination of a rapamycin and an antiestrogen in the treatment or inhibition of estrogen receptor positive carcinoma, particularly breast and ovarian cancer.
Breast cancer is a leading cause of female cancer deaths in the world. The growth of some human breast cancer cells is under hormonal control. Substantial evidence suggests that estrogen promotes the development of breast cancer. The biological effect of estrogen in the breast is mediated by estrogen receptor (ER), which is a member of a large family of ligand-inducible transcription factors. Upon binding to its receptor, the ligand initiates the dissociation of heat shock proteins from the receptor, receptor dimerization, phosphorylation, and binding to DNA response elements of target genes. After binding to DNA, ER differentially regulates transcription of target genes with or without other transcription factors and coactivators/corepressors. Estrogen action can be partially blocked by antagonists (antiestrogens) which act through ER in a way that is competitive with estrogen but fails to activate genes that promote cell growth. The antiestrogen tamoxifen (Tam) has been the first-line therapy in the treatment and management of breast cancer based on the estrogen responsiveness for stimulation of tumor growth. Unfortunately, the effectiveness of Tam therapy is hampered by its agonist activity in other tissues such as the uterus and side effects like hot flashes. There is a need to develop new antiestrogens or to develop optimal combinations of antiestrogens with other therapeutic agents to achieve better efficacy and reduce side effects.
Rapamycin is a macrocyclic triene antibiotic produced by
Streptomyces hygroscopicus,
which was found to have antifungal activity, particularly against
Candida albicans,
both in vitro and in vivo [C. Vezina et al., J. Antibiot. 28, 721 (1975); S. N. Sehgal et al., J. Antibiot. 28, 727 (1975); H. A. Baker et al., J. Antibiot. 31, 539 (1978); U.S. Pat. Nos. 3,929,992; and 3,993,749]. Additionally, rapamycin alone (U.S. Pat. No. 4,885,171) or in combination with picibanil (U.S. Pat. No. 4,401,653) has been shown to have antitumor activity.
A rapamycin ester, rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid [disclosed in U.S. Pat. No. 5,362,718], also known as CCI-779, has been shown to have antitumor activity against a variety of tumor cell lines, in in vivo animal tumor models, and in Phase I clinical trials. [Gibbons, J., Proc. Am. Assoc. Can. Res. 40: 301 (1999); Geoerger, B., Proc. Am. Assoc. Can. Res. 40: 603 (1999); Alexandre, J., Proc. Am. Assoc. Can. Res. 40: 613 (1999); and Alexandre, J., Clin. Cancer. Res. 5 (November Supp.): Abstr. 7 (1999)].
Non-uterotrophic antiestrogens have been reported to have antitumor activity [see, U.S. Pat. No. 5,998,402]. 2-(4-Hydroxy-phenyl)-3-methyl-1-[4-(2-piperdin-1-yl-ethoxy)-benzyl-1H-indol-5-ol, also known as ERA-923, has been reported as being developed for the treatment of estrogen receptor positive metastatic breast cancer. [Gandhi, T., 2000 ASCO Program/Proceedings, Abstract 875, (May 2000)].
REFERENCES:
patent: 4316885 (1982-02-01), Rakhit
patent: 4650803 (1987-03-01), Stella et al.
patent: 5023263 (1991-06-01), Von Burg
patent: 5023264 (1991-06-01), Caufield et al.
patent: 5100883 (1992-03-01), Schiehser
patent: 5118677 (1992-06-01), Caufield
patent: 5118678 (1992-06-01), Kao et al.
patent: 5120842 (1992-06-01), Failli et al.
patent: 5130307 (1992-07-01), Failli et al.
patent: 5151413 (1992-09-01), Caufield et al.
patent: 5162333 (1992-11-01), Failli et al.
patent: 5177203 (1993-01-01), Failli et al.
patent: 5221670 (1993-06-01), Caufield
patent: 5233036 (1993-08-01), Hughes
patent: 5256790 (1993-10-01), Nelson
patent: 5258389 (1993-11-01), Goulet et al.
patent: 5260300 (1993-11-01), Hu
patent: 5262423 (1993-11-01), Kao
patent: 5302584 (1994-04-01), Kao et al.
patent: 5362718 (1994-11-01), Skotnicki et al.
patent: 5373014 (1994-12-01), Failli et al.
patent: 5378836 (1995-01-01), Kao et al.
patent: 5385908 (1995-01-01), Nelson et al.
patent: 5385909 (1995-01-01), Nelson et al.
patent: 5385910 (1995-01-01), Ocalin
patent: 5389639 (1995-02-01), Failli
patent: 5391730 (1995-02-01), Skotnicki
patent: 5411967 (1995-05-01), Kao et al.
patent: 5434260 (1995-07-01), Skotnicki et al.
patent: 5463048 (1995-10-01), Skotnicki et al.
patent: 5480988 (1996-01-01), Failli et al.
patent: 5480989 (1996-01-01), Kao et al.
patent: 5489680 (1996-02-01), Failli et al.
patent: 5491231 (1996-02-01), Nelson et al.
patent: 5504091 (1996-04-01), Molnar-Kimber et al.
patent: 5563145 (1996-10-01), Failli et al.
patent: 5665772 (1997-09-01), Cottens et al.
patent: 5780462 (1998-07-01), Lee et al.
patent: 5998402 (1999-12-01), Miller et al.
patent: WO97 48397 (1997-12-01), None
patent: WO99 63974 (1999-12-01), None
Frost Philip
Greenberger Lee Martin
Sadler Tammy M.
Zhang Yixian
Krass Frederick
Milowsky Arnold S.
Wyeth
LandOfFree
Method of treating estrogen receptor positive carcinoma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating estrogen receptor positive carcinoma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating estrogen receptor positive carcinoma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3021260